Immunocore Streamlines Leadership to Advance Clinical Ambitions

Biotechnology firm Immunocore Holdings is implementing a strategic reorganization of its research leadership, aiming to create a more efficient structure for guiding its clinical pipeline. The changes, centered on internal promotions following an executive departure, are designed to accelerate progress toward the company's key 2026 milestones.

The company confirmed that Dr. David Berman will step down from his role as head of Research & Development, effective February 27. Rather than seeking an external replacement, Immunocore is redistributing responsibilities to two seasoned internal leaders to tighten the integration between clinical development and regulatory strategy.

Under the new framework, Dr. Mohammed Dar has been elevated to Executive Vice President of Clinical Development. Concurrently, Mark Moyer assumes the position of Chief Regulatory and Quality Officer. Moyer brings extensive regulatory expertise, having played a pivotal role in securing the initial market approval for Immunocore's drug, KIMMTRAK.

This reshuffle intends to ensure seamless continuation of the company's active programs, which include three Phase 3 trials. The leadership consolidation reflects a deliberate move to streamline decision-making as Immunocore focuses on expanding KIMMTRAK's applications and pursuing new indications in melanoma.

Should investors sell immediately? Or is it worth buying Immunocore Holdings?

Pipeline and Financial Calendar in Focus

The success of this operational realignment will be measured by the advancement of Immunocore's ambitious clinical roadmap. A significant period for the company will be the second half of 2026, when critical clinical readouts are anticipated for two major candidates.

• Data for the asset Brenetafusp in ovarian and lung cancer is expected.
• Results for the candidate IMC-P115C are also slated for that window.
• Furthermore, the company plans to submit an application to begin clinical trials for a new candidate in autoimmune diseases during the latter half of 2026.

Investors will gain a clearer picture of the company's financial footing to support these costly late-stage trials when Immunocore releases its full-year 2025 financial results. This disclosure is currently scheduled for February 25.

While the upcoming financial report will provide essential context, the true test for investor sentiment is likely to come later. The clinical data expected in late 2026 will be decisive in evaluating the long-term potential of Immunocore's leading drug candidates.